{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:00:16Z","timestamp":1790622016266,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2020YFC2008304"],"award-info":[{"award-number":["2020YFC2008304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this study is to investigate the key factors influencing the extent of DDI between cyclosporine A (CsA, GtoPdb Ligand ID: 2162) and voriconazole (VCZ, GtoPdb Ligand ID: 6424)\/posaconazole (PCZ, GtoPdb Ligand ID: 6426) in Chinese paediatric allo\u2010HSCT recipients and to establish evidence\u2010based dose adjustment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>One\u2010hundred\u2010four children were enrolled and already taking stable doses of oral CsA when voriconazole or posaconazole was initiated. Evaluate the CsA dose and body weight\u2010adjusted dose\u2010normalized concentration (C\/D) required to achieve therapeutic trough concentration (Cmin) before and after initiation of voriconazole or posaconazole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CsA C\/D increased by 173.37% during VCZ co\u2010therapy and 132.90% during PCZ co\u2010therapy. The magnitude of change in CsA C\/D was significantly associated with\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      (GtoPdb Enzyme ID: 1043) genotype and PCZ Cmin. For maintaining therapeutic CsA exposure, the required percentage reduction in CsA dose varied according to\n                      <jats:italic>CYP3A5<\/jats:italic>\n                      (GtoPdb Enzyme ID: 1040) genotype and age. In the VCZ group, dose reductions ranged from 22.22% to 43.47% across age and\n                      <jats:italic>CYP3A5<\/jats:italic>\n                      genotype subgroups. In the PCZ group, dose reductions ranged from 12.77% to 33.34% across corresponding subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      genotype and PCZ Cmin independently affect the magnitude of the DDI between CsA and VCZ\/PCZ in paediatric allo\u2010HSCT patients, and\n                      <jats:italic>CYP3A5<\/jats:italic>\n                      genotype and age of children should be integrated to guide individualized CsA dose reduction when co\u2010administered with VCZ or PCZ.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70609","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:24:49Z","timestamp":1780025089000},"page":"3354-3364","source":"Crossref","is-referenced-by-count":0,"title":["Impact of voriconazole\/posaconazole on CsA in paediatric allogeneic haematopoietic stem cell transplantation recipients: A real\u2010world study"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3767-6998","authenticated-orcid":false,"given":"Meng\u2010Meng","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Pharmacy First Affiliated Hospital of Zhengzhou University  Zhengzhou China"},{"name":"Henan Engineering Research Center for Application and Translation of Precision Clinical Pharmacy Zhengzhou University  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics First Affiliated Hospital of Zhengzhou University  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy First Affiliated Hospital of Zhengzhou University  Zhengzhou China"},{"name":"Henan Engineering Research Center for Application and Translation of Precision Clinical Pharmacy Zhengzhou University  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.05.017"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703928"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20710"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213913"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.08.019"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401\u2010019\u20100277\u2010x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30723\u20103"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.1"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13293"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.02.001"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00623\u201021"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2351"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.11.028"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02230\u201017"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1734\u20101140(11)70594\u20101"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.12.1730"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.38"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010022\u201003378\u2010z"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.6.825"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12751"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.575463"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00207\u201021"},{"key":"e_1_2_10_25_1","unstructured":"Pfizer Inc.VFEND I.V. (voriconazole for injection); VFEND tablets (voriconazole); VFEND (voriconazole for oral suspension) package insert. New York NY.2020"},{"key":"e_1_2_10_26_1","unstructured":"Schering Corporation.Noxafil (posaconazole) oral suspension package insertKenilworth NJ 2022"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bth457"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12016"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01489\u201012"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.4103\/jrpp.JRPP_16_163"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.05.024"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065599"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015577798"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2020.02.001"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14232"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70609","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70609","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:55:30Z","timestamp":1790618130000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/bcp.70609"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70609","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}